William Blair Reiterates “Outperform” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “outperform” rating reiterated by research analysts at William Blair in a research report issued to clients and investors on Tuesday,RTT News reports.

A number of other research firms have also issued reports on SRPT. Wall Street Zen lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 26th. Morgan Stanley upped their target price on shares of Sarepta Therapeutics from $15.00 to $20.00 and gave the company an “equal weight” rating in a report on Tuesday. Scotiabank upgraded shares of Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 target price on the stock in a report on Friday, June 6th. JPMorgan Chase & Co. upgraded shares of Sarepta Therapeutics from an “underweight” rating to a “neutral” rating and set a $24.00 target price on the stock in a report on Tuesday. Finally, Leerink Partners restated a “market perform” rating on shares of Sarepta Therapeutics in a report on Monday, July 21st. Six analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $49.12.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $16.75 on Tuesday. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $145.00. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. The firm’s 50-day simple moving average is $24.69 and its 200 day simple moving average is $62.20. The firm has a market capitalization of $1.65 billion, a PE ratio of -6.23 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million during the quarter, compared to analysts’ expectations of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. Sarepta Therapeutics’s revenue for the quarter was up 80.2% on a year-over-year basis. During the same quarter last year, the company posted $0.73 earnings per share. On average, equities research analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Institutional Trading of Sarepta Therapeutics

Several large investors have recently bought and sold shares of the company. Capital International Investors grew its position in Sarepta Therapeutics by 38.9% in the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares in the last quarter. Farallon Capital Management LLC grew its position in Sarepta Therapeutics by 11.1% in the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after acquiring an additional 285,100 shares in the last quarter. Wellington Management Group LLP grew its position in Sarepta Therapeutics by 27.9% in the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock valued at $168,907,000 after acquiring an additional 577,848 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in Sarepta Therapeutics by 2.1% in the first quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company’s stock valued at $127,512,000 after acquiring an additional 41,408 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Sarepta Therapeutics by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company’s stock valued at $207,538,000 after acquiring an additional 9,999 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.